Advertisement
J. Lipid Res.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mahley, R. W.
Right arrow Articles by Rall, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mahley, R. W.
Right arrow Articles by Rall, S. C., , Jr.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 40, 1933-1949, November 1999
Copyright © 1999 by Lipid Research, Inc.


Review

Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes

Robert W. Mahleya,b,c, Yadong Huanga,b, and Stanley C. Rall, Jr.a
a Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, CA 94141-9100
b Cardiovascular Research Institute, University of California, San Francisco, CA 94141-9100
c Departments of Medicine and Pathology, University of California, San Francisco, CA 94141-9100

Correspondence to: Robert W. Mahley

Type III hyperlipoproteinemia (HLP) is a genetic disorder characterized by accumulation of remnant lipoproteins in the plasma and development of premature atherosclerosis. Although receptor binding-defective forms of apolipoprotein (apo) E are the common denominator in this disorder, a number of apparent paradoxes concerning its pathogenesis still exist. However, studies in transgenic animals are resolving the mechanisms underlying this disorder. Paradox I: Defective apoE (commonly apoE2) is essential but not sufficient to cause overt type III HLP. In fact, most apoE2 homozygotes are hypolipidemic. Studies in apoE2 transgenic models have demonstrated the impact of other genes or hormones in converting the hypolipidemia to hyperlipidemia. Paradox II: Among apoE2 homozygotes, men are more susceptible than women to type III HLP. Transgenic studies have shown that estrogen affects both LDL receptor expression and lipolytic processing, explaining the resistance of women to this disorder until after menopause. Paradox III: ApoE deficiency is associated with hypercholesterolemia, whereas the type III HLP phenotype is characterized by both hypercholesterolemia and hypertriglyceridemia. The hypercholesterolemia is caused by impaired receptor-mediated clearance, whereas the hypertriglyceridemia is caused primarily by impaired lipolytic processing of remnants and increased VLDL production associated with increased levels of apoE. Paradox IV: ApoE2 is associated with recessive inheritance of this disorder, whereas other defective apoE variants are associated with dominant inheritance. Determinants of the mode of inheritance are the differential binding of apoE variants to the LDL receptor versus the HSPG/LRP complex and the preference of certain apoE variants for specific lipoproteins. Thus, the pathogenesis of this sometimes mysterious disorder has been clarified.—Mahley, R. W., Y. Huang, and S. C. Rall, Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J. Lipid Res. 1999. 40: 1933;–1949.

Supplementary key words: apolipoprotein E, lipoprotein metabolism, heparan sulfate proteoglycans, LDL receptor, lipolysis, ß-VLDL, VLDL production, hypercholesterolemia, hypertriglyceridemia, remnant lipoproteins


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Reproductive SciencesHome page
A. Basaran
Pregnancy-induced Hyperlipoproteinemia: Review of the Literature
Reproductive Sciences, May 1, 2009; 16(5): 431 - 437.
[Abstract] [PDF]


Home page
J. Lipid Res.Home page
R. W. Mahley, K. H. Weisgraber, and Y. Huang
Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS
J. Lipid Res., April 1, 2009; 50(Supplement): S183 - S188.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. Wu, H. Yang, Y. Zhao, C. Sharan, J. S. Goodwin, L. Zhou, Y. Guo, and Z. Guo
2-Aminopurine Inhibits Lipid Accumulation Induced by Apolipoprotein E-Deficient Lipoprotein in Macrophages: Potential Role of Eukaryotic Initiation Factor-2{alpha} Phosphorylation in Foam Cell Formation
J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 395 - 405.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Fan, S. Qiu, C. D. Overton, P. G. Yancey, L. L. Swift, W. G. Jerome, M. F. Linton, and S. Fazio
Impaired Secretion of Apolipoprotein E2 from Macrophages
J. Biol. Chem., May 4, 2007; 282(18): 13746 - 13753.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. E. Mullick, A. F. Powers, R. S. Kota, S. D. Tetali, J. P. Eiserich, and J. C. Rutledge
Apolipoprotein E3- and Nitric Oxide-Dependent Modulation of Endothelial Cell Inflammatory Responses
Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 339 - 345.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. W. Mahley, K. H. Weisgraber, and Y. Huang
Inaugural Article: Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease
PNAS, April 11, 2006; 103(15): 5644 - 5651.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Heeren, U. Beisiegel, and T. Grewal
Apolipoprotein E Recycling: Implications for Dyslipidemia and Atherosclerosis
Arterioscler. Thromb. Vasc. Biol., March 1, 2006; 26(3): 442 - 448.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
J. Ruiz, D. Kouiavskaia, M. Migliorini, S. Robinson, E. L. Saenko, N. Gorlatova, D. Li, D. Lawrence, B. T. Hyman, K. H. Weisgraber, et al.
The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor
J. Lipid Res., August 1, 2005; 46(8): 1721 - 1731.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
P Maheux
Dermatology spot diagnosis
Postgrad. Med. J., August 1, 2005; 81(958): 497 - 497.
[Full Text] [PDF]


Home page
Clin. Chem.Home page
D. J. Blom, F. H. O'Neill, and A. D. Marais
Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations
Clin. Chem., May 1, 2005; 51(5): 904 - 907.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Futamura, P. Dhanasekaran, T. Handa, M. C. Phillips, S. Lund-Katz, and H. Saito
Two-step Mechanism of Binding of Apolipoprotein E to Heparin: IMPLICATIONS FOR THE KINETICS OF APOLIPOPROTEIN E-HEPARAN SULFATE PROTEOGLYCAN COMPLEX FORMATION ON CELL SURFACES
J. Biol. Chem., February 18, 2005; 280(7): 5414 - 5422.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
W. Marz, H. Scharnagl, M. M. Hoffmann, B. O. Boehm, and B. R. Winkelmann
The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study)
Eur. Heart J., December 1, 2004; 25(23): 2109 - 2119.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. T. Janis, S. Siggins, E. Tahvanainen, R. Vikstedt, K. Silander, J. Metso, A. Aromaa, M.-R. Taskinen, V. M. Olkkonen, M. Jauhiainen, et al.
Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample
J. Lipid Res., December 1, 2004; 45(12): 2303 - 2309.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
K. M. Mann, F. E. Thorngate, Y. Katoh-Fukui, H. Hamanaka, D. L. Williams, S. Fujita, and B. T. Lamb
Independent effects of APOE on cholesterol metabolism and brain A{beta} levels in an Alzheimer disease mouse model
Hum. Mol. Genet., September 1, 2004; 13(17): 1959 - 1968.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
K. Ikewaki, W. Cain, F. Thomas, R. Shamburek, L. A. Zech, D. Usher, H. B. Brewer Jr., and D. J. Rader
Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency
J. Lipid Res., July 1, 2004; 45(7): 1302 - 1311.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
L. Krimbou, M. Denis, B. Haidar, M. Carrier, M. Marcil, and J. Genest Jr.
Molecular interactions between apoE and ABCA1: impact on apoE lipidation
J. Lipid Res., May 1, 2004; 45(5): 839 - 848.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T.B. Twickler, G.M. Dallinga-Thie, J.S. Cohn, and M.J. Chapman
Elevated Remnant-Like Particle Cholesterol Concentration: A Characteristic Feature of the Atherogenic Lipoprotein Phenotype
Circulation, April 27, 2004; 109(16): 1918 - 1925.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Saito, P. Dhanasekaran, F. Baldwin, K. H. Weisgraber, M. C. Phillips, and S. Lund-Katz
Effects of Polymorphism on the Lipid Interaction of Human Apolipoprotein E
J. Biol. Chem., October 17, 2003; 278(42): 40723 - 40729.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
R. M. DeKroon, M. Mihovilovic, Z. V. Goodger, J. B. Robinette, P. M. Sullivan, A. M. Saunders, and W. J. Strittmatter
ApoE genotype-specific inhibition of apoptosis
J. Lipid Res., August 1, 2003; 44(8): 1566 - 1573.
[Abstract] [Full Text] [PDF]


Home page
Annals of Clinical & Laboratory ScienceHome page
H. Hidaka, M. Tozuka, B. Meyer, K. Yamauchi, M. Sugano, T. Nakabayashi, and T. Katsuyama
Characterization of Triglyceride Rich Lipoproteins with Very Light Density by Ultracentrifugation and Agarose Gel Electrophoresis using Triglyceride- and Cholesterol-Staining
Ann. Clin. Lab. Sci., April 1, 2003; 33(2): 167 - 178.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Hara, T. Matsushima, H. Satoh, N. Iso-o, H. Noto, M. Togo, S. Kimura, Y. Hashimoto, and K. Tsukamoto
Isoform-Dependent Cholesterol Efflux From Macrophages by Apolipoprotein E Is Modulated by Cell Surface Proteoglycans
Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 269 - 274.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
D. J. Blom, P. Byrnes, S. Jones, and A. D. Marais
Non-denaturing polyacrylamide gradient gel electrophoresis for the diagnosis of dysbetalipoproteinemia
J. Lipid Res., January 1, 2003; 44(1): 212 - 217.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. N. Ginsberg
New Perspectives on Atherogenesis: Role of Abnormal Triglyceride-Rich Lipoprotein Metabolism
Circulation, October 15, 2002; 106(16): 2137 - 2142.
[Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. E. Hinsdale, P. M. Sullivan, H. Mezdour, and N. Maeda
ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice
J. Lipid Res., September 1, 2002; 43(9): 1520 - 1528.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. Usui, Y. Hara, S. Hosaki, and M. Okazaki
A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC
J. Lipid Res., May 1, 2002; 43(5): 805 - 814.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
I. Jialal and S. Devaraj
Remnant Lipoproteins: Measurement and Clinical Significance
Clin. Chem., February 1, 2002; 48(2): 217 - 219.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. S. Bernstein, M. C. Costanza, R. W. James, M. A. Morris, F. Cambien, S. Raoux, and A. Morabia
Physical Activity May Modulate Effects of ApoE Genotype on Lipid Profile
Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 133 - 140.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. P. Libeu, S. Lund-Katz, M. C. Phillips, S. Wehrli, M. J. Hernaiz, I. Capila, R. J. Linhardt, R. L. Raffai, Y. M. Newhouse, F. Zhou, et al.
New Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E
J. Biol. Chem., October 12, 2001; 276(42): 39138 - 39144.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
S. Lund-Katz, S. Wehrli, M. Zaiou, Y. Newhouse, K. H. Weisgraber, and M. C. Phillips
Effects of polymorphism on the microenvironment of the LDL receptor-binding region of human apoE
J. Lipid Res., June 1, 2001; 42(6): 894 - 901.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
R. H. Eckel
Familial Combined Hyperlipidemia and Insulin Resistance : Distant Relatives Linked by Intra-abdominal Fat?
Arterioscler. Thromb. Vasc. Biol., April 1, 2001; 21(4): 469 - 470.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
M. M. HOFFMANN, H. SCHARNAGL, E. PANAGIOTOU, W. T. BANGHARD, H. WIELAND, and W. MÄRZ
Diminished LDL Receptor and High Heparin Binding of Apolipoprotein E2 Sendai Associated with Lipoprotein Glomerulopathy
J. Am. Soc. Nephrol., March 1, 2001; 12(3): 524 - 530.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
K. J. Hockey, R. A. Anderson, V. R. Cook, R. R. Hantgan, and R. B. Weinberg
Effect of the apolipoprotein A-IV Q360H polymorphism on postprandial plasma triglyceride clearance
J. Lipid Res., February 1, 2001; 42(2): 211 - 217.
[Abstract] [Full Text]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
F. K. Welty, A. H. Lichtenstein, P. H. R. Barrett, J. L. Jenner, G. G. Dolnikowski, and E. J. Schaefer
Effects of ApoE Genotype on ApoB-48 and ApoB-100 Kinetics With Stable Isotopes in Humans
Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1807 - 1810.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. D. Tagalakis, I. R. Graham, D. R. Riddell, J. G. Dickson, and J. S. Owen
Gene Correction of the Apolipoprotein (Apo) E2 Phenotype to Wild-type ApoE3 by in Situ Chimeraplasty
J. Biol. Chem., April 13, 2001; 276(16): 13226 - 13230.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Knouff, S. Malloy, J. Wilder, M. K. Altenburg, and N. Maeda
Doubling Expression of the Low Density Lipoprotein Receptor by Truncation of the 3'-Untranslated Region Sequence Ameliorates Type III Hyperlipoproteinemia in Mice Expressing the Human ApoE2 Isoform
J. Biol. Chem., February 2, 2001; 276(6): 3856 - 3862.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement